Ghia P, et al. - In the DUO trial, researchers studied dose-modification patterns and their impact on response to duvelisib (DUV), a first-in-class oral dual PI3K-δ,γ inhibitor. According to the NCI CTCAE v4.03, treatment-emergent AEs (TEAEs) were assessed. To manage TEAEs, dose interruptions (DI) or reductions (DR) to 15, 10, or 5 mg BID were permitted per study protocol. Utilizing descriptive statistics, responses were evaluated by an independent review committee before and after dose modifications and were analyzed. The median duration of DUV exposure was 11.6 mo among 158 DUV-treated patients. According to findings, DI/DR can help to manage TEAEs effectively with DUV. These results indicate that DI > 1-2 weeks or more does not seem to have a significant effect on DUV or PFS reaction. Diarrhea, followed by neutropenia and pneumonia or colitis was the most common cause of DI.